Skip to main content

Ligand Design for Alpha1 Adrenoceptors

Buy Article:

$63.00 plus tax (Refund Policy)


An area of continuing interest in medicinal chemistry is the design, synthesis and pharmacological evaluation of ligands which bind at adrenoceptor subtypes, which include alpha 1A , alpha 1B ,alpha 1D ; alpha 2A , alpha 2B , alpha 2C beeta 1 , beeta 2 , beeta 3 and possibly beeta 4 subtypes. The selective blockade or stimulation of these receptor subtypes is of on-going pharmacological and medicinal interest. However, the design principles for ligand differentiation at these subtypes still need further development. This review focuses on alpha 1 adrenoceptors with a concentration on literature over the past five years. Structural, physiological and therapeu-tic aspects of the alpha 1A , alpha 1B and alpha 1D subtypes are discussed together with ligands binding to these receptor subtypes. Approaches to alpha 1 adrenoceptor ligand design based on known ligands and on receptor docking are evaluated. A new combined approach using pharmacophores and receptor docking affords possibilities for deeper insights into achieving small molecule binding selectivity.

Keywords: Adrenoceptor Ligands; Adrenoceptors; Alpha1; Antagonisits; Imidazoline; Ligands; Pharmacohores; Receptor docking; Subtype; Subtype selective

Document Type: Review Article


Publication date: May 1, 2001

More about this publication?
  • Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of the current topics in medicinal chemistry. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more